Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Greenleaf Trust

Greenleaf Trust raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,827 shares of the biopharmaceutical company's stock after acquiring an additional 2,279 shares during the quarter. Greenleaf Trust's holdings in Gilead Sciences were worth $3,230,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC acquired a new position in shares of Gilead Sciences during the first quarter worth about $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the first quarter worth about $29,000. Core Alternative Capital grew its position in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC grew its position in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares in the last quarter. Finally, Investment Research & Advisory Group Inc. grew its position in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 100 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Gilead Sciences stock traded up $1.30 during trading hours on Thursday, hitting $114.54. The stock had a trading volume of 6,096,837 shares, compared to its average volume of 7,692,113. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The stock has a market capitalization of $142.48 billion, a price-to-earnings ratio of 24.11, a PEG ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a 1-year low of $67.65 and a 1-year high of $119.96. The stock's fifty day moving average is $107.40 and its two-hundred day moving average is $104.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the previous year, the firm earned ($1.32) EPS. The business's revenue for the quarter was down .3% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.76%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of analyst reports. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. JPMorgan Chase & Co. upped their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, Morgan Stanley upped their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $111.38.

Insider Buying and Selling

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the sale, the chief executive officer directly owned 615,725 shares in the company, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $330,510.00. Following the completion of the sale, the insider owned 120,168 shares in the company, valued at $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 58,500 shares of company stock worth $6,340,745 in the last three months. Corporate insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.